Latest Insider Transactions at Aurinia Pharmaceuticals Inc. (AUPH)

AUPH Quotes by TradingView

This section provides a real-time view of insider transactions for Aurinia Pharmaceuticals Inc. (AUPH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Aurinia Pharmaceuticals Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Aurinia Pharmaceuticals Inc.'s insiders and make more informed investment decisions.

Insider Transaction List

Date Insider Transaction Ownership Type Shares Traded Value / Price
Mar 07 2025
Greg Keenan Chief Medical Officer
SELL
Open market or private sale
Direct
8,305 -5.13%
$66,440 $8.23 P/Share
Mar 04 2025
Peter Greenleaf Chief Executive Officer
SELL
Open market or private sale
Direct
164,947 -8.44%
$1,154,629 $7.92 P/Share
Mar 04 2025
Matthew Maxwell Donley Chief Operating Officer
SELL
Open market or private sale
Direct
58,991 -7.98%
$412,937 $7.92 P/Share
Mar 04 2025
Stephen P. Robertson EVP, General Counsel
SELL
Open market or private sale
Direct
57,607 -10.16%
$403,249 $7.92 P/Share
Mar 04 2025
Joseph M Miller Chief Financial Officer
SELL
Open market or private sale
Direct
56,154 -8.86%
$393,078 $7.92 P/Share
Mar 04 2025
Tang Kevin C
BUY
Open market or private purchase
Indirect
748,038 +2.44%
$5,984,304 $8.0 P/Share
Mar 03 2025
Greg Keenan Chief Medical Officer
SELL
Open market or private sale
Direct
12,239 -7.03%
$97,912 $8.0 P/Share
Mar 03 2025
Peter Greenleaf Chief Executive Officer
SELL
Open market or private sale
Direct
195,593 -9.1%
$1,564,744 $8.0 P/Share
Mar 03 2025
Peter Greenleaf Chief Executive Officer
BUY
Grant, award, or other acquisition
Direct
333,705 +13.44%
-
Mar 03 2025
Matthew Maxwell Donley Chief Operating Officer
SELL
Open market or private sale
Direct
65,902 -8.18%
$527,216 $8.0 P/Share
Mar 03 2025
Stephen P. Robertson EVP, General Counsel
SELL
Open market or private sale
Direct
64,872 -10.27%
$518,976 $8.0 P/Share
Mar 03 2025
Stephen P. Robertson EVP, General Counsel
BUY
Grant, award, or other acquisition
Direct
102,406 +13.95%
-
Mar 03 2025
Joseph M Miller Chief Financial Officer
SELL
Open market or private sale
Direct
61,859 -8.9%
$494,872 $8.0 P/Share
Mar 03 2025
Joseph M Miller Chief Financial Officer
BUY
Grant, award, or other acquisition
Direct
114,711 +14.16%
-
Mar 03 2025
Tang Kevin C
BUY
Open market or private purchase
Indirect
452,682 +2.38%
$3,168,774 $8.0 P/Share
Feb 28 2025
Greg Keenan Chief Medical Officer
BUY
Grant, award, or other acquisition
Direct
62,583 +26.45%
-
Feb 28 2025
Peter Greenleaf Chief Executive Officer
BUY
Grant, award, or other acquisition
Direct
290,728 +13.8%
-
Feb 28 2025
Matthew Maxwell Donley Chief Operating Officer
BUY
Grant, award, or other acquisition
Direct
82,781 +11.0%
-
Feb 28 2025
Stephen P. Robertson EVP, General Counsel
BUY
Grant, award, or other acquisition
Direct
84,106 +13.71%
-
Feb 28 2025
Joseph M Miller Chief Financial Officer
BUY
Grant, award, or other acquisition
Direct
81,457 +12.3%
-
Feb 28 2025
Tang Kevin C
BUY
Open market or private purchase
Indirect
399,280 +4.33%
$2,794,960 $7.85 P/Share
Dec 09 2024
Tang Kevin C
BUY
Open market or private purchase
Indirect
500,000 +5.6%
$4,500,000 $9.09 P/Share
Dec 06 2024
Tang Kevin C
BUY
Open market or private purchase
Indirect
400,000 +4.8%
$3,600,000 $9.01 P/Share
Dec 05 2024
Tang Kevin C
BUY
Open market or private purchase
Indirect
300,000 +3.83%
$2,400,000 $8.91 P/Share
Nov 21 2024
Jill Leversage Director
BUY
Grant, award, or other acquisition
Direct
12,135 +32.63%
-
Nov 21 2024
Karen L. Smith Director
BUY
Grant, award, or other acquisition
Direct
12,135 +32.85%
-
Nov 21 2024
Jeffrey Allen Bailey Director
BUY
Grant, award, or other acquisition
Direct
12,135 +32.25%
-
Nov 21 2024
Craig A Johnson Director
BUY
Grant, award, or other acquisition
Direct
20,631 +50.0%
-
Nov 21 2024
David R.W. Jayne Director
BUY
Grant, award, or other acquisition
Direct
12,135 +17.68%
-
Nov 11 2024
Jeffrey Allen Bailey Director
SELL
Open market or private sale
Direct
4,557 -25.44%
$36,456 $8.43 P/Share
Nov 11 2024
Karen L. Smith Director
SELL
Open market or private sale
Direct
5,241 -29.26%
$41,928 $8.43 P/Share
Nov 08 2024
Jeffrey Allen Bailey Director
BUY
Exercise of conversion of derivative security
Direct
17,913 +50.0%
-
Nov 08 2024
Karen L. Smith Director
BUY
Exercise of conversion of derivative security
Direct
17,913 +50.0%
-
Aug 06 2024
Scott Michael Habig Chief Commercial Officer
SELL
Open market or private sale
Direct
18,249 -3.85%
$91,245 $5.31 P/Share
May 21 2024
Brinda Balakrishnan Director
SELL
Open market or private sale
Direct
520 -2.88%
$2,600 $5.74 P/Share
May 21 2024
Jill Leversage Director
SELL
Open market or private sale
Direct
5,610 -30.28%
$28,050 $5.74 P/Share
May 21 2024
David R.W. Jayne Director
SELL
Open market or private sale
Direct
4,946 -10.03%
$24,730 $5.74 P/Share
May 21 2024
Daniel Billen Director
SELL
Open market or private sale
Direct
5,252 -15.73%
$26,260 $5.74 P/Share
May 21 2024
R. Hector Mac Kay Dunn
SELL
Open market or private sale
Direct
5,630 -23.24%
$28,150 $5.74 P/Share
Mar 06 2024
Joseph M Miller Chief Financial Officer
SELL
Open market or private sale
Direct
34,811 -6.56%
$174,055 $5.6 P/Share
Mar 06 2024
Peter Greenleaf Chief Executive Officer
SELL
Open market or private sale
Direct
126,981 -7.7%
$634,905 $5.6 P/Share
Mar 06 2024
Stephen P. Robertson EVP, General Counsel
SELL
Open market or private sale
Direct
57,745 -11.51%
$288,725 $5.6 P/Share
Mar 06 2024
Scott Michael Habig Chief Commercial Officer
SELL
Open market or private sale
Direct
17,777 -3.61%
$88,885 $5.6 P/Share
Mar 06 2024
Matthew Maxwell Donley Chief Operating Officer
SELL
Open market or private sale
Direct
40,665 -6.51%
$203,325 $5.51 P/Share
Feb 27 2024
Volker Knappertz EVP, Research and Development
SELL
Open market or private sale
Direct
4,930 -1.52%
$29,580 $6.1 P/Share
Feb 20 2024
Volker Knappertz EVP, Research and Development
SELL
Open market or private sale
Direct
25,146 -7.2%
$125,730 $5.48 P/Share
Feb 20 2024
Matthew Maxwell Donley Chief Operating Officer
BUY
Grant, award, or other acquisition
Direct
216,666 +25.75%
-
Feb 20 2024
Scott Michael Habig Chief Commercial Officer
SELL
Open market or private sale
Direct
15,867 -3.12%
$79,335 $5.48 P/Share
Feb 20 2024
Scott Michael Habig Chief Commercial Officer
BUY
Grant, award, or other acquisition
Direct
195,512 +27.78%
-

Track Institutional and Insider Activities on AUPH

Follow Aurinia Pharmaceuticals Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AUPH shares.

Notify only if
Any

Insider Trading

Get notified when an Aurinia Pharmaceuticals Inc. insider buys or sells AUPH shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to Aurinia Pharmaceuticals Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on AUPH